Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Lanreotide (Somatuline) Peptide
Long-acting somatostatin analog for acromegaly and NETs.
What is Lanreotide (Somatuline)?
Lanreotide (Somatuline) is a somatostatin analog · oncology peptide studied for acromegaly and gastroenteropancreatic nets. Below is an educational overview of Lanreotide (Somatuline) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Somatuline Depot
Acromegaly, neuroendocrine tumors of the GI tract and pancreas, carcinoid syndrome.
A deep monthly injection that mimics somatostatin to slow growth-hormone excess and certain neuroendocrine tumors.
- •Diarrhea
- •Abdominal pain
- •Gallstones
- •Nausea
- •Injection-site reactions
- •Gallbladder disease
- •Bradycardia / heart-rate changes
- •Glucose changes
- •Hypothyroidism
- •Hypersensitivity to lanreotide
- •Severe untreated cardiac conduction disease
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Lanreotide (Somatuline) Mechanism of Action
Cyclic octapeptide somatostatin analog with high affinity for SSTR2 and SSTR5. Suppresses GH secretion and slows progression of gastroenteropancreatic neuroendocrine tumors.
Lanreotide (Somatuline) Research Areas & Benefits
Lanreotide (Somatuline) Dosage & Common Research Protocols
Deep subcutaneous 60–120 mg every 4 weeks.
Protocols summarized for educational reference from published research. Not dosing guidance.
Lanreotide (Somatuline) Studies & Cited Research
CLARINET trial
Lanreotide significantly prolonged progression-free survival in enteropancreatic NETs.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Lanreotide (Somatuline) Side Effects & Safety Considerations
- •FDA-approved.
- •Monitor gallbladder, glucose, and thyroid function.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.